GlassScriptPhysician profile
Amy C Jackson
NPI 1679623672
$2,419.25
in general payments reported to CMS, 2019-2025
25 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $476 · 2023: $729 · 2024: $391 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Education: $13.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.14 |
| Education | $13.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $280.94 | 2021-2025 | |
| Abbott Laboratories | $253.21 | 2023 | Amplatzer, Epic |
| Abbvie INC. | $225.23 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $185.75 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $184.05 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $183.59 | 2021-2024 | |
| Lilly USA, LLC | $177.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $126.83 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $115.71 | 2021-2022 | |
| Mylan Specialty L.P. | $104.10 | 2022-2024 | Yupelri |
| Avanir Pharmaceuticals, INC. | $86.91 | 2021-2022 | |
| Axsome Therapeutics, INC. | $83.25 | 2023-2025 | Auvelity |
| Amgen INC. | $74.58 | 2021-2024 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $59.43 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $47.25 | 2024 | Nuzyra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $39.09 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.85 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $29.22 | 2023-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $23.69 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.20 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.59 | 2023 | |
| Mallinckrodt Hospital Products INC. | $17.36 | 2025 | Acthar |
| Ferring Pharmaceuticals INC. | $16.86 | 2022 | |
| Genentech USA, INC. | $14.49 | 2021 | |
| Exact Sciences Corporation | $13.84 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.